Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock
Sponsor: Northern Jiangsu People's Hospital
Summary
The purpose of this study is to evaluate the efficacy and safety of the combination therapy of hydrocortisone and fludrocortisone among adult patients with septic shock.
Official title: Initiation of Hydrocortisone and Fludrocortisone in Adult Patients With Septic Shock：A Prospective Randomized Controlled Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
336
Start Date
2026-03-02
Completion Date
2028-12-31
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
Hydrocortisone plus Fludrocortisone
Hydrocortisone will be administered at a dose of 200 mg per day by continuous intravenous infusion. Fludrocortisone will be administered at a dose of 50 μg once daily orally or via nasogastric tube. Both drugs will be given for up to 7 days or until ICU discharge, whichever occurs first.
Standard care
Patients will receive standard care for septic shock according to current international and institutional guidelines, including fluid resuscitation, vasopressor therapy, antimicrobial treatment, and other supportive measures. Fludrocortisone will not be administered.Hydrocortisone may be administered at the discretion of the treating physician.
Locations (1)
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China